Mazdutide clinical trials
Mazdutide is named as an intervention in 20 current clinical trials in our China and USA registers. 8 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Innovent Biologics (Suzhou) Co. Ltd (7). The most-studied condition is Obesity.
How Mazdutide works
All drug targets →- OverweightPhase 3
- DementiaPhase 3
- Hypertensive disorderPhase 3
- Obesity disorderPhase 3
- Obstructive sleep apnea syndromePhase 3
- Type 2 diabetes mellitusPhase 3
- Metabolic dysfunction-associated steatohepatitisPhase 2
- Polycystic ovary syndromePhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5095358, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13924, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Mazdutide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Mazdutide
20 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Mazdutide
30 conditionsAll 30 conditions
| Condition (as registered) | Trials |
|---|---|
| Obesity | 8 |
| Overweight | 5 |
| Type 2 Diabetes | 3 |
| Obesity & Overweight | 2 |
| Fatty Pancreas | 1 |
| Heart Failure With Preserved Ejection Fraction (HFPEF) | 1 |
| Heart Failure With Mildly Reduced Ejection Fraction | 1 |
| Sleep Apnea | 1 |
| Obstructive | 1 |
| Adolescents With Obesity or Overweight With Weight-Related Comorbidities | 1 |
| Metabolic Dysfunction-associated Steatohepatitis (MASH) | 1 |
| Atypical Endometrial Hyperplasia | 1 |
| Endometrial Carcinoma Stage I | 1 |
| Hypertensive | 1 |
| Dementia, Mild | 1 |
| Mild Cognitive Impairment | 1 |
| Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | 1 |
| Weight Control | 1 |
| Prediabetes | 1 |
| Impaired Fasting Glucose | 1 |
| Impaired Glucose Tolerance (Prediabetes) | 1 |
| Type 2 Diabetic Kidney Disease | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Metabolic Dysfunction-Associated Steatohepatitis | 1 |
| Hepatic Steatosis | 1 |
| Living Liver Donors | 1 |
| Coronary Heart Disease | 1 |
| Atrial Fibrillation (AF) | 1 |
| Ablation Treatment | 1 |
| Mazdutide | 1 |
Sponsors
lead sponsor per trialBy country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 19 | 7 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Mazdutide trials
How many clinical trials are testing Mazdutide?
20 current trials in our China and USA registers name Mazdutide (also registered as LY3305677) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Mazdutide trials recruiting patients?
Yes. 8 of the 20 trials are recruiting: 7 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Mazdutide clinical trials?
Innovent Biologics (Suzhou) Co. Ltd (7), Tongji Hospital (2), Eli Lilly and Company (1) and The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1), among 13 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Mazdutide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Mazdutide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Mazdutide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.